Evaluating Mobile-based Medication Reconciliation by Patients at Home (PILLS@HOME)
Evaluating Mobile-based Medication Reconciliation by Patients at Home: Feasibility, Quality and Time Investments by Pharmacy Technicians
Medication reconciliation (MR) is essential to limit drug-related problems that occur during care transitions in and out of care institutions. Pharmacy-led medication reconciliation has been shown to reduce medication discrepancies, preventable harm and hospital readmissions. However, these consultations are time-consuming. The Erasmus Medical Center is currently developing a mobile-based patient portal. After receiving an invitation to perform medication reconciliation in the app, patients can review their medication and allergies at home. Next, pharmacy technicians manually verify all patient-entered data on completeness and quality. The investigators hypothesize that mobile-based medication reconciliation results in increased patient insight. Yet, it is unknown if mobile-based medication reconciliation is feasible, saves time, and is of high quality.
Therefore, the primary study objectives are to assess (1) the feasibility of patients performing medication reconciliation using a mobile-based patient portal, (2) the time investment of pharmacy technicians in mobile-based medication reconciliation (and related costs), in comparison to standard practice, and (3) the quality of patients' pre-verified medication lists. The secondary study objective is to assess patients' and pharmacy technicians' acceptability of performing medication reconciliation using a mobile-based patient portal.
This is a prospective quality evaluation study assessing mobile-based medication reconciliation. All adult patients (18 years or older) who are admitted to (a selection of) clinical ward in Erasmus Medical Center and who are asked to complete medication reconciliation are eligible. In the patient app, patients review ('pre-verify') their medications and allergies, after which pharmacy technicians check and manually approve ('verify') all patient-entered data and determine whether a follow-up interview is needed.
Feasibility is defined as the successful completion rate of digital medication reconciliation, and the need for additional interviews. Time investment by pharmacy technicians (and related costs) are determined by timing the duration of all patient-bound medication reconciliation-related tasks, both in standard care and when using mobile-based reconciliation. The quality of verification is determined by comparing patients' pre-verified medication list to pharmacy technician-verified lists. Acceptability is defined as the perceived usability of medication reconciliation by patients and by pharmacy technicians.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Martijn Brands, MD
- Phone Number: 0031205665675
- Email: m.r.brands@erasmusmc.nl
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18 years or older
- Planned admission to the clinical ward of participating pilot departments in Erasmus MC
Exclusion Criteria:
- No potential subject will be excluded from participation in this study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Users of mobile-based medication-reconciliation app
Adult patients (18 years or older) who are asked to complete medication reconciliation before a planned admission to the clinical ward of selected pilot departments in Erasmus Medical Center
|
Erasmus Medical Center is developing a state-of-the-art, mobile-based patient portal that combines up-to-date medication lists from all healthcare providers involved in a patient's care.
Other functionalities include: accessing health information, viewing and planning appointments, teleconsulting, sending messages, filling in questionnaires, reporting self-measurements, and reading background information on diseases, medication, and other interventions.
The patient portal will primarily be implemented in Erasmus Medical Center, and is ultimately intended for every patient, regardless of underlying condition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility (1/4): completion rate of digital MR by patients
Time Frame: During quality evaluation of the patient app, an average of 3 months
|
The fraction of all patients who were invited to participate that participated
|
During quality evaluation of the patient app, an average of 3 months
|
|
Feasibility (2/4): the time it takes patients to perform digital MR (in minutes)
Time Frame: During quality evaluation of the patient app, an average of 3 months
|
To assess the ease-of-use of performing medication reconciliation in the patient app
|
During quality evaluation of the patient app, an average of 3 months
|
|
Feasibility (3/4): the need for live, follow-up interviews after performing digital MR
Time Frame: During quality evaluation of the patient app, an average of 3 months
|
The fraction of all patients who were invited to participate in digital MR who needed a live interview
|
During quality evaluation of the patient app, an average of 3 months
|
|
Feasibility (4/4): how often the helpdesk was contacted
Time Frame: During quality evaluation of the patient app, an average of 3 months
|
The fraction of all patients who were invited to participate in digital MR who contact the helpdesk
|
During quality evaluation of the patient app, an average of 3 months
|
|
The time investment by pharmacy technicians per patient in the digital MR process, compared to the current situation (in minutes)
Time Frame: Before launch of the patient app, during an average of 2 months, and during quality evaluation of the patient app, an average of 3 months
|
The time investment by pharmacy technicians per patient in the new workflow vs. the current situation, in which all patients are invited for a live interview
|
Before launch of the patient app, during an average of 2 months, and during quality evaluation of the patient app, an average of 3 months
|
|
The quality of a patient's pre-verified medication list, compared to the pharmacy technician's verified medication list
Time Frame: During quality evaluation of the mobile-based medication reconciliation tool, an average of 3 months
|
The number of discrepancies between the patient-reported medication list and the pharmacy-verified medication list (the number of changes made by a pharmacy technician in the MR process)
|
During quality evaluation of the mobile-based medication reconciliation tool, an average of 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability (1/2): defined as the perceived usability of mobile-based MR by patients, assessed using short in-app questionnaires (VAS 1-5)
Time Frame: During quality evaluation of the mobile-based medication reconciliation tool, an average of 3 months
|
To assess to what extent digital medication reconciliation is accepted by patients
|
During quality evaluation of the mobile-based medication reconciliation tool, an average of 3 months
|
|
Acceptability (2/2): defined as the perceived usability of mobile-based MR by patients and pharmacy technicians, assessed using short qualitative interviews with both patients and pharmacy technicians
Time Frame: During quality evaluation of the mobile-based medication reconciliation tool, an average of 3 months
|
To assess to what extent digital medication reconciliation is accepted by patients and pharmacy technicians
|
During quality evaluation of the mobile-based medication reconciliation tool, an average of 3 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 10624
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.